Long/post-COVID in children and adolescents: symptom onset and recovery after one year based on healthcare records in Germany.

Autor: Ehm F; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany. franz.ehm@ukdd.de., Tesch F; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany., Menzer S; IKK Classic, Tannenstraße 4 B, 01099, Dresden, Germany., Loser F; Techniker Krankenkasse, Bramfelder Straße 140, 22305, Hamburg, Germany., Bechmann L; IKK Classic, Tannenstraße 4 B, 01099, Dresden, Germany., Vivirito A; InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski-Straße 5, 10249, Berlin, Germany., Wende D; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany., Batram M; Vandage GmbH, Detmolder Str. 30, 33604, Bielefeld, Germany., Buschmann T; AOK PLUS, Sternplatz 7, 01067, Dresden, Germany., Ludwig M; InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski-Straße 5, 10249, Berlin, Germany., Roessler M; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany., Seifert M; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany., Sarganas Margolis G; Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany., Reitzle L; Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany., Koenig C; Techniker Krankenkasse, Bramfelder Straße 140, 22305, Hamburg, Germany., Schulte C; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany., Ballesteros P; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany., Bassler S; AOK PLUS, Sternplatz 7, 01067, Dresden, Germany., Bitterer T; IKK Classic, Tannenstraße 4 B, 01099, Dresden, Germany., Riederer C; DAK-Gesundheit, Nagelsweg 27 - 31, 20097, Hamburg, Germany., Berner R; Department of Pediatrics, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany., Scheidt-Nave C; Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany., Schmitt J; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany., Toepfner N; Department of Pediatrics, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
Jazyk: angličtina
Zdroj: Infection [Infection] 2024 Sep 16. Date of Electronic Publication: 2024 Sep 16.
DOI: 10.1007/s15010-024-02394-8
Abstrakt: Purpose: Evidence on the incidence and persistence of post-acute sequelae of COVID-19 (PASC) among children and adolescents is still limited.
Methods: In this retrospective cohort study, 59,339 children and adolescents with laboratory-confirmed COVID-19 in 2020 and 170,940 matched controls were followed until 2021-09-30 using German routine healthcare data. Incidence rate differences (ΔIR) and ratios (IRR) of 96 potential PASC were estimated using Poisson regression. Analyses were stratified according to age (0-11, 12-17 years), and sex. At the individual level, persistence of diagnoses in patients with onset symptoms was tracked starting from the first quarter post-infection.
Results: At 0-3 month follow-up, children and adolescents with a previous SARS-CoV-2 infection showed a 34% increased risk of adverse health outcome, and approximately 6% suffered from PASC in association with COVID-19. The attributable risk was higher among adolescents (≥ 12 years) than among children. For most common symptoms, IRRs largely persisted at 9-12 month follow-up. IRR were highest for rare conditions strongly associated with COVID-19, particularly inflammatory conditions among children 0-11 years, and chronic fatigue and respiratory insufficiency among adolescents. Tracking of diagnoses at the individual level revealed similar rates in the decline of symptoms among COVID-19 and control cohorts, generally leaving less than 10% of the patients with persistent diagnoses after 12 months.
Conclusion: Although very few patients presented symptoms for longer than 12 months, excess morbidity among children and, particularly, adolescents with a history of COVID-19 means a relevant burden for pediatric care.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: